Pharmacy Staff Considerations for Implementing Bispecific T-cell Engager Therapies

This Pharmacy Staff considerations list has been developed to help cancer centers adopt the use of Bispecific T-cell Engager therapies.

The information provided herein is intended to help provide operational considerations when administering Bispecific T-cell Engager therapies. The considerations below are for general informational purposes only, and it is the responsibility of the healthcare provider to refer to the recommendations in specific product labeling as applicable.

BEFORE TREATMENT (PRIOR TO FIRST DOSE)

- **Consider speaking to relevant stakeholders about Bispecific T-cell Engager therapy**
  - Check the product label for any premedications, concomitant medications, or other treatments that may be required
  - Check the product label for expected side effects and their management strategies
- **Check the product label to ensure that the Bispecific T-cell Engager therapy is prepared and stored per the manufacturer's recommendations**
- **Review Bispecific T-cell Engager therapy orders that have been written/ordered by provider**
- **Check the product label to ensure premedications or concomitant medications for toxicity management are available at the pharmacy in case they are needed**
- **Review pretreatment laboratory assessments included in the product label to ensure treatment requirements are met prior to admixture**
- **Educate patients/caregivers on potential toxicities of Bispecific T-cell Engager therapy. Advise on the following:**
  - Signs and symptoms of adverse events
  - Refer to the full Prescribing Information, including the Patient Information

DURING ADMINISTRATION (DAY OF TREATMENT)

- **Follow strictly the preparation instructions provided in the product label to prevent underdosing or overdosing of Bispecific T-cell Engager therapy**
  - Calculate dose as per manufacturer's recommendations (ie, accounting for priming the IV line to ensure a full dose)
- **Assist nursing staff in troubleshooting infusion or dosing issues if need arises**
- **Monitor patients for potential toxicities and coordinate with clinical team in its management when necessary.[1] This may include recommending:**
  - Supportive medications for symptom management
  - Dosing modifications per the product label
  - Treatment interruption, re-initiation, or termination per the product label

POST ADMINISTRATION (AFTER EACH DOSE AND END OF TREATMENT)

- **Reinforce education on potential toxicities of Bispecific T-cell Engager therapy with patient/caregiver[1]**
- **Advise patients to contact the designated clinical staff member in case of emergency or to report concerning symptoms based on the product label[1]**

IV, intravenous.

Reference: 1. Association of Community Cancer Centers. https://www.accc-cancer.org/docs/projects/bispecific-antibodies/checklist-for-bispecific-antibodies-jan-2022.pdf?sfvrsn=ad2f3ee4_2. Accessed April 16, 2024.

USA-OCF-82502 4/24

AMGEN